Skip to main content

PharmaZell-Novasep merger complete

Following negotiations begun in September 2021, PharmaZell, a German-based supplier of speciality APIs, and Novasep, a CDMO focused on complex small molecules and ADCs, have closed their merger under the majority ownership of Bridgepoint Group. Former PharmaZell CEO Dr Sylke Hassel (pictured) will be CEO, while former Novasep CEO Michel Spagnol has joined the board of directors.

PharmaZell and Novasep to merge

PharmaZell, a German-based producer of speciality APIs, and France’s CDMO Groupe Novasep are to merge under the ownership of PharmaZell’s current majority shareholder, private equity firm Bridgepoint. This remains subject to consultation with employees and other closing conditions.

Subscribe to PharmaZell